Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | MTOR | P42345 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.58 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676522 | 1.00 | LMNA (0.62) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL21184966 | 1.00 | LMNA (0.62) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL9293560 | 0.84 | SLC28A1 (0.59) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL4293684 | 0.84 | SLC28A1 (0.59) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL13657982 | 0.84 | SLC28A1 (0.59) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL352974 | 0.84 | SLC28A1 (0.59) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL12594002 | 0.84 | SLC28A1 (0.59) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL29260505 | 0.78 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7028245 | 0.78 | MAPT (0.63) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7028251 | 0.78 | MAPT (0.63) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010047698-A1 | ACTIVATION-INDUCED CYTIDINE DEAMINASE INHIBITOR SUPPRESSION OF AUTOIMMUNE DISEASES | UNIVERSITY OF ALABAMA AT BIRMINGHAM (US) | 2010-04-29 | — | — | WO | claimed |
| CN-116942816-A | Application of SNIP1 as target spot in preparation or screening of antitumor drugs | 苏州青锐生物科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3436601-B1 | CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET | CENTRE NAT RECH SCIENT (FR) | 2023-03-29 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-11209421-B2 | Cytidine deaminase expression level in cancer as a new therapeutic target | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-12-28 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2005118817-A1 | METHOD FOR HIGH SPEED SCREENING FOR THE IDENTIFICATION OF MOLECULES INHIBITING THE ACTIVITY OF EDITING ENZYMES | OBE THERAPY BIOTECHNOLOGY (FR) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005115410-A2 | CONTEXT DEPENDENT INHIBITORS OF CYTIDINE DEAMINASES AND USES THEREOF | UNIVERSITY OF ROCHESTER (US) | 2005-12-08 | — | — | WO | disclosed |
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |
| EP-1379549-A2 | SEQUENCE OF THE PHOTORHABDUS LUMINESCENS STRAIN TT01 GENOME AND USES | INSTITUT PASTEUR (FR) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002094867-A2 | SEQUENCE OF THE PHOTORHABDUS LUMINESCENS STRAIN TT01 GENOME AND USES | INSTITUT PASTEUR (FR) | 2002-11-28 | — | — | WO | disclosed |
| EP-0159264-B1 | ANTIVIRAL COMPOUNDS | MERCK & CO. INC. (US) | 1991-07-24 | — | — | EP | disclosed |
| EP-0210639-B1 | 4-AMINO-3-HALO-2-PYRIDINONE NUCLEOSIDE AND NUCLEOTIDE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | LMNA 2870/4885MTOR 3437/4885THRB 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.